The genomic afterlife of cancer therapy
Journal of Clinical Investigation · 02.11.2026 · 136 (21)
DOI: 10.1172/jci213544 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 02.11.2026. Verfasst von Xiaolu Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
- Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.
- Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Förderung
- NCI NIH HHS
Zitieren
APA
Wang, X., & Sethi, N. S. (2026). The genomic afterlife of cancer therapy. Journal of Clinical Investigation, 136(21). https://doi.org/10.1172/jci213544
Vancouver
Wang X, Sethi NS. The genomic afterlife of cancer therapy. Journal of Clinical Investigation. 2026;136(21). doi:10.1172/jci213544
BibTeX
@article{Wang2026,
author = {Wang, Xiaolu and Sethi, Nilay S},
title = {The genomic afterlife of cancer therapy},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {21},
doi = {10.1172/jci213544}
}
EUVIMED